$0.6
Market Capitalization | 1.7M |
Book Value | - $7.7 |
Earnings Per Share (EPS) | -16.0 |
Wall Street Target Price | 72.0 |
Profit Margin | -291.89% |
Operating Margin TTM | -291.03% |
Return On Assets TTM | -53.69% |
Return On Equity TTM | -426.64% |
Revenue TTM | 12.0M |
Revenue Per Share TTM | 5.51 |
Quarterly Revenue Growth YOY | 0.0% |
Gross Profit TTM | 79.8M |
EBITDA | -34.9M |
Diluted Eps TTM | -16.0 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -26.72 |
EPS Estimate Next Year | -18.8 |
EPS Estimate Current Quarter | -0.61 |
EPS Estimate Next Quarter | -0.45 |
What analysts predicted
Upside of 11900.0%
Sell
Neutral
Buy
Aslan Pharmaceuticals Ltd is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|
Bvf Inc
Velan Capital Investment Management LP
Shay Capital LLC
Sio Capital Management, LLC
Schonfeld Strategic Advisors LLC
Renaissance Technologies Corp
aslan pharmaceuticals (aslan, 6497.tt) is a clinical-stage oncology-focused biopharmaceutical company developing novel therapeutics for global markets. aslan targets diseases that are both highly prevalent in asia and orphan indications in the united states and europe. led by a senior management team with extensive experience in global and regional development and commercialization, aslan is headquartered in singapore and has offices in taiwan and china. aslan’s portfolio is comprised of four product candidates which target validated growth pathways applied to new patient segments, novel immune checkpoints and novel cancer metabolic pathways. aslan’s partners include array biopharma, bristol-myers squibb, almirall and csl.
Organization | Aslan Pharmaceuticals Ltd |
Employees | 35 |
CEO | Dr. Carl Alan Jason Morton Firth EMBA, Ph.D. |
Industry | Health Technology |
A Spac I Acquisition Corp
$0.60
+0.0%
Keyarch Acquisition Corp
$0.60
+0.0%
Connexa Sports Technologies Inc
$0.60
+0.0%
Us Value Etf
$0.60
+0.0%
First Wave Biopharma Inc
$0.60
+0.0%
Global X Msci Next Emerging
$0.60
+0.0%
Fat Projects Acquisition Corp
$0.60
+0.0%
Capital Link Global Fintech
$0.60
+0.0%
Applied Uv Inc
$0.60
+0.0%